Kodiak Sciences (KOD) Stock Price, News & Analysis

Company Overview

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Key Stats

• Today's Range: $8.39 to $9.00
• 50-Day Range: $3.53 to $8.84
• 52-Week Range: $1.92 to $11.60
• Volume: 480,013 shs
• Average Volume: 420,297 shs
• Market Capitalization: $454.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Kodiak Sciences Stock Analysis - MarketRank™

Kodiak Sciences scored higher than 52% of companies evaluated by MarketBeat, and ranked 544th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Kodiak Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Kodiak Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.45) to ($3.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kodiak Sciences is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kodiak Sciences is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kodiak Sciences has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.12% of the float of Kodiak Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kodiak Sciences has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Kodiak Sciences has recently increased by 12.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kodiak Sciences does not currently pay a dividend.

Dividend Growth

Kodiak Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.87

Percentage of Shares Shorted

5.12% of the float of Kodiak Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kodiak Sciences has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Kodiak Sciences has recently increased by 12.67%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.92

News Sentiment

Kodiak Sciences has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Kodiak Sciences this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kodiak Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.90% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KOD Stock Analysis - Frequently Asked Questions

How have KOD shares performed this year?

Kodiak Sciences' stock was trading at $9.95 at the beginning of 2025. Since then, KOD stock has decreased by 11.0% and is now trading at $8.8550.

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NASDAQ:KOD) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.20.

When did Kodiak Sciences IPO?

Kodiak Sciences (KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.

Who are Kodiak Sciences' major shareholders?

Kodiak Sciences' top institutional shareholders include Acadian Asset Management LLC (3.73%), Geode Capital Management LLC (1.50%), American Century Companies Inc. (0.15%) and XTX Topco Ltd (0.08%). Insiders that own company stock include John A Borgeson and Jason Ehrlich.
View institutional ownership trends.

How do I buy shares of Kodiak Sciences?

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Datadog (DDOG), CrowdStrike (CRWD), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Splunk (SPLK).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/13/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KOD
• CIK: 1468748
• Web: kodiak.com
• Phone: (650) 281-0850
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kodiak Sciences: $9.00
• High Price Target: $20.00
• Low Price Target: $3.00
• Potential Upside/Downside: +5.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$176.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.71%
• Return on Assets: -54.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.62
• Quick Ratio: 4.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.86 per share
• Price / Book: 2.98

Miscellaneous

• Outstanding Shares: 52,760,000
• Free Float: 28,545,000
• Market Cap: $449.52 million
• Optionable: Optionable
• Beta: 2.41